Léna Pessarossi, Marilyne Poirée, Jean-Hugues Dalle, Sandrine Visentin, Carine Domenech, C. Rénard, Cécile Pochon, André Baruchel, Mony Fahd, V Gandemer, Charlotte Jubert, Stéphane Ducassou, Catherine Paillard, Laura Olivier‐Gougenheim, Alexandre Théron, Dominique Plantaz, Marie-Dominique Tabone, G. Leverger, Justyna Kanold, Sandrine Thouvenin‐Doulet, Zeinab Hamidou, Mohamed Boucékine, Julie Berbis, Pascal Auquier, Gérard Michel, Paul Saultier
Hematopoietic stem cell transplantation (HSCT) is essential for curing high-risk or relapsed acute leukemia but entails lifelong morbidities. Adolescents and young adults may be particularly vulnerable; however, data on the global risk of long-term complications in survivors who underwent HSCT during adolescence are lacking. Using the French Leucémie Enfant Adolescent cohort, we compared late complications and quality of life (QoL) in survivors transplanted at ≥15 versus <15 yr. We included 168 adolescents (≥15 yr of age at HSCT) and 446 children (<15 yr of age at HSCT) matched at best 1:3 on sex, type of leukemia, total body irradiation use, history of relapse, and follow-up duration. Cumulative morbidity was modelled with a five-state multistate model (0 to ≥4 complications). After a mean follow-up of 8.8 yr for adolescents and 9.5 yr for children, adolescents had a mean of 2.1 ± 0.1 complications compared with 1.6 ± 0.1 in younger survivors (P < .001). Higher incidences were noted for cardiomyopathy, chronic kidney disease, secondary neoplasms, iron overload, and osteonecrosis. The multi-state model revealed earlier onset and faster accumulation of complications in adolescents. QoL scores did not differ between groups. HSCT during adolescence is associated with earlier and heavier long-term morbidity, underscoring the need for age-tailored survivorship care and integration of adolescent and young adults-specific risks into follow-up guidelines.